close
1.

図書

図書
contributors, K. Agrawal ... [et al.] ; editor, James W. Fisher
出版情報: Berlin ; Tokyo : Springer-Verlag, c1992
シリーズ名: Handbook of experimental pharmacology ; v. 101
所蔵情報: loading…
2.

論文(リポジトリ)

論文(リポジトリ)
Mitsuma, Wataru ; Ito, Masahiro ; Kodama, Makoto ; Fuse, Koichi ; Okamura, Kazuki ; Minagawa, Shiro ; Kato, Kiminori ; Hanawa, Haruo ; Toba, Ken ; Nakazawa, Mikio ; Aizawa, Yoshifusa
出版情報: Biochemical and Biophysical Research Communications.  344  pp.987-994,  2006-03.  Elsevier
本文リンク: http://hdl.handle.net/10191/1165
概要: Erythropoietin (EPO) has been known to have cytoprotective effects on several types of tissues, presumably through modulation of apoptosis and inflammation. The effect of EPO on myocardial inflammation, however, has not yet been clarified. We investigated the cardioprotective effects of EPO in rats with experimental autoimmune myocarditis (EAM). Seven-week-old Lewis rats immunized with cardiac myosin were treated either with EPO or vehicle and were examined on day22. EPO attenuated the functional and histological severity of EAM along with suppression of mRNAs of tumor necrosis factor (TNF)-a and interleukin (IL)-6 in the hearts as well as a reduction of apoptotic cardiomyocytes. The EPO receptor (EPO-R) was upregulated in the myocardium of EAM compared with that of healthy rats. These results may suggest that EPO ameliorated the progression of EAM by modulating myocardial inflammation and apoptosis. 続きを見る
3.

論文(リポジトリ)

論文(リポジトリ)
鍛冶, 昌孝 ; 大橋, 靖 ; 武藤, 祐一 ; 高木, 律男 ; 服部, 幸男 ; 福田, 純一 ; 染矢, 源治
出版情報: 新潟歯学会雑誌 — 新潟歯学会雑誌.  27  pp.37-43,  1997-07.  新潟歯学会
本文リンク: http://hdl.handle.net/10191/23003
概要: Two hundred and ninety-one operative cases, who received autologous blood transfusions in our department from June 1988 to December 1996, were studied clinico-statistically. There were 274 cases of jaw deformities, 8 cases of malignant tumors and 5 cases of benign tumors. Autologous blood transfusion increased year by year, and consequently the rate of autologous blood transfusion among blood transfusions was above 90% after 1995. Recently homologous blood transfusion have not been required except for malignant tumors. The effects of recombinant human erythropoietin (EPO) and iron preparations (Fe) were investigated. The results were as follows: In the EPO and Fe group, just after autologous blood collection of 800ml the mean values for Hb and Ht were 0.90 and 0.90 of the baseline values before autologous blood collection, respectively. And in 4 to 14 days after surgery the mean values were 0.96 and 0.96, respectively. In the EPO and Fe group, Hb and Ht recovered after the surgery more quickly than in the control group.<br />今回、当科における自己血輸血症例について検討し、エリスロポエチン(EPO)、鉄剤の効果についても若干の知見を得たので報告する。対象は、最近8年7か月間に自己血輸血で手術を行った291症例とした。自己血輸血症例数の年度別推移では、年々増加傾向にあり1995年以降は50症例を越すようになっていた。それに伴い同種血輸血症例数が減少し、悪性腫瘍手術以外では同種血輸血の必要性がなくなっていた。疾患別では顎変形症が274例,悪性腫瘍が8例,良性腫瘍が5例であった。EPO、鉄剤の効果について800ml採血症例をEPO、鉄剤投与群,、剤単独投与群、非投与群の3群に分類し検討した。EPO、鉄剤投与群、鉄剤単独投与群、非投与群のヘモグロビン値の採血前値はそれぞれ13.0、13.2、14.8g/dlであり、この値を初期値とすると採血後、術後(4~14日)の初期値に対する比はEPO、鉄剤投与群では0.90から0.96、鉄剤単独投与群では0.86から0.88とそれぞれ上昇、非投与群では0.90から0.79へと減少した。また,ヘマトクリット値に関しては鉄剤+EPO投与群、鉄剤単独投与群、非投与群の採血前値はそれぞれ38.8%、38.9%、45.0%であり、採血後、術後の初期値に対する比はEPO、鉄剤投与群では0.90、0.96と上昇、鉄剤投与群ではそれぞれ0.89、非投与群では0.90、0.79と減少した。以上、EPO、鉄剤投与群で術後早期のヘモグロビン、ヘマトクリット値の回復が認められた。 続きを見る